BSX
Boston Scientific Corporation
BSX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over BSX overall, supported by stronger fundamentals and stronger modeled upside.
BSX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
BSX's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BSX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $44.20 | — |
| Cheap | 18x | $43.27 | -2.1% |
| Current | 19x | $44.20 | — |
| Fair | 64x | $151 | +241% |
| Expensive | 90x | $211 | +378% |
Historical ranges are pointers, not guarantees.
BSX's PE is in its cheap range at 19x. On analysts' estimates for next year's earnings, today's price would be 14x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over BSX in the historical PE scenario, which offers more potential upside but is not a forecast.
BSX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Moderate | |
| High |
Analysts expect BSX's earnings, revenue and profitability to hold roughly steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over BSX on the outlook, with more favorable earnings and revenue expectations.
BSX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.09 | +31% |
| Q3 2026 | $2.36 | +26% |
| Q2 2026 | $2.47 | +47% |
| Q1 2026 | $2.39 | +74% |
| Q4 2025 | $1.94 | +55% |
| Q3 2025 | $1.87 | +55% |
| Q2 2025 | $1.68 | +37% |
| Q1 2025 | $1.37 | +15% |
| Q4 2024 | $1.25 | +17% |
BSX has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
BSX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +1.4% |
| Q2 2026 | $5.4B | +7.5% |
| Q1 2026 | $5.2B | +12% |
| Q4 2025 | $5.3B | +16% |
| Q3 2025 | $5.1B | +20% |
| Q2 2025 | $5.1B | +23% |
| Q1 2025 | $4.7B | +21% |
| Q4 2024 | $4.6B | +22% |
BSX's revenue has grown year over year for 23 quarters in a row: $5.1B last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -4.6 points |
| Q2 2026 | 22% | +5.5 points |
| Q1 2026 | 21% | +1.4 points |
| Q4 2025 | 16% | +0.8 points |
| Q3 2025 | 21% | +3.3 points |
| Q2 2025 | 16% | +3.6 points |
| Q1 2025 | 20% | +2.2 points |
| Q4 2024 | 15% | -0.9 points |
BSX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BSX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BSX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $868M | -25% |
| Q2 2026 | $1.3B | +13% |
| Q1 2026 | $171M | -52% |
| Q4 2025 | $1B | -14% |
| Q3 2025 | $1.2B | +41% |
| Q2 2025 | $1.1B | +72% |
| Q1 2025 | $354M | +$369M |
| Q4 2024 | $1.2B | +71% |
BSX generated $3.3B in free cash flow over the past year, down 13% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BSX on cash flow, with more consistent year-over-year improvement.
BSX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -22.8M shares |
| 1 year | -2.9% | -43.5M shares |
| 3 years | -1.6% | -23M shares |
| 5 years | +1.1% | +16.4M shares |
| Available history | +2.9% | +41.4M shares |
BSX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BSX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.7x | Moderate |
BSX's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BSX on leverage, with a lower net debt burden relative to earnings.
BSX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 25.4 | Neutral |
BSX's weekly RSI is 40 (neutral) and its Stochastic is 25 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BSX PE vs Healthcare Sector
| Metric | BSX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 17 | 29 | 12 pts below |
BSX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over BSX on valuation relative to its sector.
BSX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.5 | 1.5% above |
| 20 week MA | $45.3 | 2.4% below |
| 50 week MA | $60.8 | 27% below |
| 100 week MA | $80.8 | 45% below |
| 200 week MA | $72.2 | 39% below |
BSX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 39% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BSX on trend strength, trading above more of its moving averages.
BSX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $45.2 | $34.6 | -24% |
| 2021 | $34.6 | $42.7 | +24% |
| 2022 | $42.7 | $46.1 | +7.8% |
| 2023 | $46.1 | $57.8 | +26% |
| 2024 | $57.8 | $90.7 | +57% |
| 2025 | $90.7 | $96.1 | +6% |
| 2026 YTD | $96.1 | $44.2 | -54% |
BSX is down 54% so far in 2026, after finishing higher in five of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BSX on returns for 2026, with the stronger performance.